- Home
- CREV vs GTBP Comparison
CREV vs GTBP Comparison
Compare CREV & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- GTBP
- Stock Information
- Founded
- CREV 2007
- GTBP 1965
- Country
- CREV Ireland
- GTBP United States
- Employees
- CREV N/A
- GTBP N/A
- Industry
- CREV
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- GTBP Health Care
- Exchange
- CREV Nasdaq
- GTBP Nasdaq
- Market Cap
- CREV 5.7M
- GTBP 5.5M
- IPO Year
- CREV N/A
- GTBP N/A
- Fundamental
- Price
- CREV $3.25
- GTBP $2.23
- Analyst Decision
- CREV
- GTBP Strong Buy
- Analyst Count
- CREV 0
- GTBP 1
- Target Price
- CREV N/A
- GTBP $11.00
- AVG Volume (30 Days)
- CREV 417.9K
- GTBP 17.4K
- Earning Date
- CREV 05-14-2025
- GTBP 05-15-2025
- Dividend Yield
- CREV N/A
- GTBP N/A
- EPS Growth
- CREV N/A
- GTBP N/A
- EPS
- CREV N/A
- GTBP N/A
- Revenue
- CREV $39,261,077.00
- GTBP N/A
- Revenue This Year
- CREV $40.76
- GTBP N/A
- Revenue Next Year
- CREV $86.18
- GTBP N/A
- P/E Ratio
- CREV N/A
- GTBP N/A
- Revenue Growth
- CREV 41.52
- GTBP N/A
- 52 Week Low
- CREV $2.00
- GTBP $1.72
- 52 Week High
- CREV $14.19
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- CREV 53.90
- GTBP 46.01
- Support Level
- CREV $2.64
- GTBP $2.30
- Resistance Level
- CREV $3.88
- GTBP $2.37
- Average True Range (ATR)
- CREV 0.50
- GTBP 0.15
- MACD
- CREV 0.02
- GTBP -0.01
- Stochastic Oscillator
- CREV 29.61
- GTBP 14.55
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.